ERIC VANCE: Open Payments
NPI 1265033435 · COLUMBUS, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$877 in 35 payments from 14 companies in 2025. Trend: 2023 $2,008 · 2024 $2,293 · 2025 $877
Food & beverage: $877
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 3 | $156 |
| Lilly USA, LLC | 6 | $147 |
| GlaxoSmithKline, LLC. | 3 | $136 |
| Novo Nordisk Inc | 6 | $120 |
| Bayer Healthcare Pharmaceuticals Inc. | 5 | $96 |
| AstraZeneca Pharmaceuticals LP | 3 | $54 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $30 |
| Lundbeck LLC | 1 | $27 |
| Exact Sciences Corporation | 1 | $25 |
| PFIZER INC. | 1 | $23 |
Products named: JARDIANCE, AREXVY, QULIPTA, Kerendia, Ozempic, REXULTI, VRAYLAR, XIFAXAN.
Industry payments across GA — which companies pay providers there.
